Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk, nearly doubled annual income and investment ...

(Reuters) - Novo Nordisk (NYSE:NVO) said on Wednesday it would discontinue its long-acting insulin Levemir in the United States,... (Reuters) - U.S. companies across sectors such as food and ...

Novo Nordisk and United Laboratories International’s subsidiary, United Biotechnology Co. have entered into a potentially $2 ...

Novo Nordisk on Monday announced a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the ...

Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...

And speaking of dividends, Novo Nordisk pays one, and it has increased its annual dividend per share by almost 284% in the ...

Beyond diabetes and obesity, Novo Nordisk is diversifying its portfolio ... recently received approval in the EU for treating haemophilia A or B with inhibitors. Alhemo is not approved in the ...

Lexicon's LX9851 targets ACSL5, a liver enzyme involved in fat metabolism that helps moderate fat accumulation and slow down ...

Novo Nordisk will pay $200 million up front, with up to $1.8 billion in additional payments down the line, The Wall Street ...

Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and ...